Stock Financial Ratios, Dividends, Split History

PFSW / PFSweb, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)166.28
Enterprise Value ($M)194.53
Book Value ($M)41.70
Book Value / Share2.18
Price / Book4.03
NCAV ($M)-34.08
NCAV / Share-1.78
Price / NCAV-5.97
Share Statistics
Common Stock Shares Outstanding 19,025,218
Common Shares Outstanding 19,025,218
Preferred Stock Shares Outstanding 0
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.04
Return on Assets (ROA)-0.02
Return on Equity (ROE)-0.10
Balance Sheet (mrq) ($M)
Quick Ratio1.08
Current Ratio1.18
Income Statement (mra) ($M)
Disposal Group Including Discontinued Operation Revenue0.00
Sales Revenue Services Net233,580,000.00
Sales Revenue Goods Net40,663,000.00
Sales Revenue Net326,825,000.00
Reimbursement Revenue52,582,000.00
Operating Income0.60
Net Income-3.96
Earnings Per Share Basic-0.21
Earnings Per Share Basic And Diluted-0.21
Earnings Per Share Diluted-0.21
Cash Flow Statement (mra) ($M)
Cash From Operations11.05
Cash from Investing-4.59
Cash from Financing11.05
Identifiers and Descriptors
Central Index Key (CIK)1095315
Related CUSIPS
717098906 071709820

Split History

Stock splits are used by PFSweb, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

PFSweb: The Rebound, And The Rally, Should Continue

2018-06-14 seekingalpha
Valuation has moved from cheap to reasonable, at 9x+ EBITDA and ~18x normalized free cash flow. (3-0)

Non-Manufacturing Grows for 100 Months in a Row: 4 Picks

2018-06-08 zacks
The non-manufacturing sector clocked the 100th consecutive month of growth in April as NMI measured by The Institute of Supply Management (ISM) touched 58.6%. Out of the 18 non-manufacturing industries, 14 reported growth. Any reading above 50 indicates that the sector is expanding and a reading above 55 is considered outstanding. (11-0)

Russell 2000's Bull Run Continues: 5 Top Small-Cap Picks

2018-06-05 zacks
Small-cap stocks continue to make hay as large-cap ones reel under the influence of severe market volatility. Several factors like inflationary concerns and impending interest rate hike, global trade war fear, geopolitical conflicts in the Middle East, political turmoil in Europe, oil price fluctuations and many more, have heightened market fluctuations. However, small-cap stocks generally remain immune to external disturbances, making them lucrative investment options in a volatile market. (6-0)

New Strong Buy Stocks for May 16th

2018-05-16 zacks
Hi-Crush Partners LP (HCLP - Free Report) : This company that provides proppant and logistics solutions has seen the Zacks Consensus Estimate for its current year earnings increasing 15.9% over the last 60 days. (21-0)

PFSweb's (PFSW) CEO Mike Willoughby on Q1 2018 Results - Earnings Call Transcript

2018-05-13 seekingalpha
Good afternoon, everyone, and thank you for participating in today's conference call to discuss PFSweb's Financial Results for the First Quarter ended March 31, 2018. (3-0)

CUSIP: 717098206